<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779970</url>
  </required_header>
  <id_info>
    <org_study_id>1.0</org_study_id>
    <nct_id>NCT04779970</nct_id>
  </id_info>
  <brief_title>COIN-B: Controlled Interruption of Nucleos(t)Ide Analogue Treatment in Chronic Hepatitis B Infections</brief_title>
  <acronym>COIN-B</acronym>
  <official_title>Controlled Interruption of Nucleos(t)Ide Analogue Treatment in Chronic Hepatitis B Patients - a Cost-benefit Analysis and Assessment of the Role of Ethnicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we will prospectively stop NA in both Caucasian and non-Caucasian patients&#xD;
      matched for gender and age, to validate the observed host and viral parameters for future&#xD;
      roll-out of this treatment strategy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An estimated 290 million people worldwide are chronically infected with the Hepatitis B Virus&#xD;
      (HBV). One fourth of untreated patients develop progressive liver damage and are at risk of&#xD;
      liver-related death, which can be prevented by treatment with Nucleos(t)ide Analogues (NA).&#xD;
      These drugs efficiently suppress viral replication, but seroclearance of the virus, defined&#xD;
      as loss of Hepatitis B surface Antigen (HBsAg), is predicted to require an average of 36 to&#xD;
      52 years (2, 3). Cessation of NA after long-term viral suppression in patients without HBV&#xD;
      seroclearance might reduce costs and may even increase the chance of subsequent HBsAg loss.&#xD;
      We have recently shown in a retrospective multicentric international study, that Caucasian&#xD;
      ethnicity and off-treatment viral control are associated with HBsAg loss after NA cessation.&#xD;
      In this study we will prospectively stop NA in both Caucasian and non-Caucasian patients&#xD;
      matched for gender and age, to validate the observed host and viral parameters for future&#xD;
      roll-out of this treatment strategy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sustained viral control at week 72 after cessation</measure>
    <time_frame>72 weeks</time_frame>
    <description>sustained viral control at week 72 after cessation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>Caucasian patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cessation of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-Caucasian patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cessation of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cessation of ongoing treatment</intervention_name>
    <description>Cessation of ongoing treatment</description>
    <arm_group_label>Caucasian patients</arm_group_label>
    <arm_group_label>non-Caucasian patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic hepatitis B: HBsAg+ or HBV DNA+ &gt;6 months&#xD;
&#xD;
          -  Under continuous NA treatment (Lamivudin, Adefovir, Tenofovir or Entecavir)&#xD;
&#xD;
          -  &gt;18 years old&#xD;
&#xD;
          -  HBeAg negative at start of treatment&#xD;
&#xD;
          -  HBV DNA undetectable &gt;36 months or &lt;100 IU/mL &gt;48 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fibrosis &gt;F2 at pre-treatment start biopsy and/or fibrosis &gt;F2 at any&#xD;
             Fibroscan/ShearWave (unless they agree for a new biopsy)&#xD;
&#xD;
          -  Coïnfection: Hepatitis C, hepatitis delta, HIV&#xD;
&#xD;
          -  Chronic immune suppressive medication&#xD;
&#xD;
          -  Ever HCC&#xD;
&#xD;
          -  Ever participated in HBV siRNA therapeutic trials&#xD;
&#xD;
          -  Participation in other HBV therapeutic intervention studies &lt;6 months before inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Vanwolleghem, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Vanwolleghem, MD PhD</last_name>
    <phone>+32 3 281 38 53</phone>
    <email>thomas.vanwolleghem@uza.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arno Furquim d'Almeida, PharmD</last_name>
    <phone>+32 3 265 26 89</phone>
    <email>arno.furquimdalmeida@uantwerpen.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ASZ Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabelle Colle, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefan Bourgeois, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas Vanwolleghem, MD PhD</last_name>
      <phone>+32 3 281 38 53</phone>
      <email>thomas.vanwolleghem@uza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GZA Antwerp</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Dirk Sprengers, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Hans Orlent, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Baro Deressa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Pierre</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas Sersté, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ULB Erasme Hospital</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Christophe Moréno, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Brussels</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Hendrik Reynaert, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Charleroi</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Sergio Negrin-Dastis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZOL Genk</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Geert Robaeys, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Christophe Vansteenkiste, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Virga Jesse Hasselt</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Filip Janssens, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Jolimont</name>
      <address>
        <city>La Louvière</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean Henrion, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Sart-Tilmann</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean Delwaide, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Damiaan</name>
      <address>
        <city>Ostend</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Mike Cool, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Wim Verlinden, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Guy Van Roey, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Upon publication of the findings</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Upon publication of the findings</ipd_time_frame>
    <ipd_access_criteria>Through request to the study chair, prof. dr. Thomas Vanwolleghem</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

